am I the only one who found retatrutide harder than the injections
am I the only one who found retatrutide harder than the injections, and I want the answer with the reasoning attached rather than just the conclusion.
Where the evidence actually stands, since every thread here assumes a different answer.
Phase 2 reported a large mean body weight change at 48 weeks across a few hundred participants with a slow, protocol-driven escalation. The effect size was striking. The confidence intervals were wide, the population was small, and the duration was under a year.
Phase 3 is running. Until it reports, everything else — including the ranking arguments this board loves — is extrapolation from a small study. That is not a criticism of the compound; it is a description of the evidence.
Kept a log specifically because there is so little published. It is one person and it is not data.
The thing that surprised me was how much of the discussion here is inference rather than measurement.
That is everything I have. The rest is opinion and I have tried to keep it out.
best — the order this archive was captured in
Trial names corrected in the title. The phase 3 programme and the phase 2 readout are not the same thing.
Independent purity testing on this compound is thin compared with the older molecules, simply because fewer members have paid for it. Fewer results means wider uncertainty, not a verdict.
Which phase 2 arm are you quoting, and at what week?
What the glucagon arm is doing, as best anyone can say from public data.
GLP-1 and GIP agonism cover appetite and insulin secretion in ways that are now reasonably well characterised. Glucagon receptor agonism is the third leg and it is associated with increased energy expenditure and with effects on hepatic fat.
Mechanistically that is why this compound reads as a different proposition rather than a stronger version of a dual agonist. Clinically, the size and durability of that difference in humans is precisely what is not yet established, and anyone telling you otherwise is filling a gap with confidence.
Yes — the glucagon arm is what makes it a different proposition rather than a stronger version of the others.
Correction: TRIUMPH is the phase 3 programme. The number you are quoting is from the phase 2 readout, which is a different trial.
Correction: TRIUMPH is the phase 3 programme.
This is the sentence the rest of the board should read first. Phase 2 is not a label.
Stopped at a low step because there was no reason to go further and no data to tell me what further would do.
Watched heart rate on a wearable across twelve weeks because the threads said to. It moved a little and I have no idea whether that means anything.
Disagree. "More receptors means more effect" is not how any of this works and the trial data does not support the linear story.
- 1What the glucagon arm is doing, as best anyone can say from public data.…6 comments in this branch · started by u/heart_rate_bump